MGB Pharma
MGB Pharma
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tolerance and Effectiveness of C14 on HPV Infection | Cancer of the Uterine Cervix, DNA Virus Infections, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, human papilloma virus infection, infectious disease, neoplasm, sexually transmitted disease, uterine disorder, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Phase 1 / Phase 2 | 2024-11-04 | NCT06672653 |